Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091130 · ClinicalTrials.gov registry record · Phase 2
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT00091130: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00091130 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091130, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomavirus and abnormal cervical cells and may be effective in preventing cervical cancer
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- BIOLOGICAL HspE7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091130
The ClinicalTrials.gov registry entry for NCT00091130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00091130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091130 about?
NCT00091130 is a clinical study titled "SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells". This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomav...
What is the current status of trial NCT00091130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2004-09.
What interventions are being tested in trial NCT00091130?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), HspE7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091130?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.